SCHEMBL30656241

SCHEMBL30656241

O=C(O)c1csc2ccc(OCc3ccccc3)cc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.56
EDNRA P25101 1/20 0.53
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
MDH2 P40926 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NR4A2 P43354 2/20 0.50
MAOB P27338 2/20 0.50
MCL1 Q07820 1/20 0.50
NR4A1 P22736 1/20 0.50
NR4A3 Q92570 1/20 0.50
SLC16A3 O15427 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.48
TNKS2 Q9H2K2 1/20 0.48
PARP2 Q9UGN5 1/20 0.48
CTSV O60911 1/20 0.47
CTSL P07711 1/20 0.47
MAOA P21397 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8695196 0.82 FFAR1 (0.64) FFAR1EDNRAFFAR4
SCHEMBL6234342 0.80 MAOB (0.51) FFAR1EDNRASMN1; SMN2MAOBTNKS2
SCHEMBL6130757 0.80 KMT2A (0.49) FFAR1EDNRASMN1; SMN2MCL1KMT2A
SCHEMBL8019368 0.78 FFAR1 (0.53) FFAR1EDNRAMEN1KMT2ATNKS2
SCHEMBL6130765 0.77 MTNR1A (0.52) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL7161222 0.76 MAOB (0.65) ALDH1A1HPGDMDH2SMN1; SMN2NR4A2
SCHEMBL1519064 0.75 MAOB (0.77) ALDH1A1HPGDMDH2SMN1; SMN2NR4A2
SCHEMBL4756552 0.75 MAOB (0.63) ALDH1A1HPGDMDH2SMN1; SMN2NR4A2
SCHEMBL6414966 0.75 MRGPRX4 (0.60) FFAR1ALDH1A1HPGDMDH2SMN1; SMN2
SCHEMBL3977036 0.75 CA12 (0.47) ALDH1A1SMN1; SMN2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 US claimed
EP-4532013-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP claimed
CN-119421879-A Novel derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-02-11 CN claimed
WO-2023227697-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO claimed
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 US disclosed
EP-4532013-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP disclosed
CN-119421879-A Novel derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-02-11 CN disclosed
WO-2023227697-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM2, TRPM6 FFAR1 1386/4885EDNRA 1582/4885ALDH1A1 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.